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Introduction. Melanoma gives rise to 7–13% brain metastases (MBM — melanoma brain metastases) and is ranked 
third leading cause of brain metastases. The prognosis of patients with MBM is poor, with a median survival time 
of 3–6 months. Assessment of the value and limitations of three prognostic scores used in patients with melanoma 
brain metastases (MBM) was presented in this paper.
Material and methods. In 110 patients with MBM, we executed an analysis of prognostic factors. All patients were 
treated with radiotherapy: whole brain radiotherapy performed as a treatment method in combination with chemo-
therapy (14 patients — 12.7%), neurosurgery (12 patients — 10.9% or stereotactic radiosurgery (8 patients — 7.3%).
Results. The median overall survival (OS) from diagnosis MBM was 4.8 months (95% CI 4.1–5.2 months). The analyses 
showed that the Karnofsky Performance Status and number of the MBM are independent significant prognostic factors. 
The analyses of OS, as a function of prognostic scores, showed that in the class with the best prognosis median OS was 
similar (7.2–10.7 months); and in the class with the worse prognosis median OS was also similar (range, 2.6–4.3 months). 
Conclusions. Our observations and data from literature showed that the presented scores can: distinguish classes 
of patients by prognosis before treatment, guide the choice of treatment methods and help design strategies for 
patient selection in clinical trials but they did not fully discriminate between unfavourable groups. 
NOWOTWORY J Oncol 2016; 66, 5: 367–374
Key words: melanoma, brain metastases, prognostic index
Introduction 
Melanoma gives rise to 7–13% of all brain metastases 
(MBM — melanoma brain metastases) and is ranked as 
third leading cause of brain metastases, after lung cancer 
(30–60%) and breast cancer (15–25%) [1–8]. The prevalence 
of melanoma brain metastases in patients with locore-
gional advancement melanoma is about 10%, whereas in 
patients with a generalised stage of the disease, it exceeds 
15–46% [1, 2, 4, 6, 8]. In almost half of the patients with 
melanoma, MBM is the cause of death, whilst autopsies 
shows the presence of MBM in 50–75% of such melanoma 
cases [1, 2, 4, 5, 8–11].
The prognosis of patients with MBM is poor with a mean 
survival of 3–6 months; in patients treated solely with cor-
ticosteroids, the mean survival is 2 months, whilst after 
the whole brain radiotherapy (WBRT) — it is about 3–4 
months [6, 8, 10, 12–16]. Numerous publication data sug-
gests that some patients may benefit from surgical treat-
ment or radio-surgery (with the application of stereotactic 
methods of radiotherapy — SBRT), where the survival pe-
riod varies between a few months and more than one year 
(12 months). This, however, concerns mostly patients with 
isolated metastatic foci (1–3 metastases, with a diameter 
up to 3.5 cm) [17–22]. 
Patients with MBM also receive systemic treatment, yet 
this kind of treatment has limited effectiveness. There are 
also attempts to undertake chemotherapy (temozolomide, 
fotemustine, thalidomide) and immunotherapy. The latter 
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method comprises the use of anti-CTLA-4 antibodies against 
cytotoxic antigen-4 of T lymphocytes (iplimumab) or BRAF 
receptor serine/threonine protein kinase inhibitors (wemu-
rafenib, dabrafenib). However, the effectiveness of systemic 
treatment is here limited; this concerns both chemotherapy 
and immunotherapy and cases of MBM in patients without 
any symptoms or whose symptoms are very limited [2, 4, 
12, 23–29].
A solid and repetitive prognostic model may be helpful 
in the selection of the treatment method and planning the 
strategy of patient selection for clinical studies in future. 
There have been many publications with prognostic indexes 
for patients with brain metastases of various types of can-
cers: RPA-RTOG (Recursive Partitioning Analysis — Radia-
tion Therapy Oncology Group), Rotterdam, SIR (Score Index 
for Radiosurgery), BSBM (Basic Score for Brain Metastases), 
Rades et al. score, GPA (Graded Prognostic Assessment), 
MM-GKR (Malignant Melanoma — Gamma Knife Radiosur-
gery), MS-GPA (melanoma-specific GPA) [30–36].
In 1997 Gaspar published the RPA index; on the basis of 
the collective analysis of the results of 3 RTOG studies, he 
distinguished some prognostic groups of patients with brain 
metastases of various types of cancers. Class I comprised 
patients below 65 years of age, with performance states (ac-
cording to the Karnofsky score — KPS) of at least 70%, with 
controlled core disease and without extracranial metastases; 
class III comprised patients with a KPS below 70%, whilst 
class II — all other remaining subjects [30].
In 2008 Sperduto proposed a new system, GPA, in which 
a specific score (0, 0.5 and 1) was attributed to 4 factors, 
being: the age (≥ 60; 50–59; < 50), the number of brain 
metastases (> 3; 2–3; 1), the KPS (< 70; 70–80; 90–100) and 
the number of extracranial metastases (none or present). 
The patients with the best prognoses received GPA 4, and 
those with the worst: 0–1 [35, 37, 38].
In 2010 Sperduto validated the previous text, taking into 
consideration the general condition of the patients and the 
number of metastatic foci, as significant prognostic factors 
in patients with MBM. The result was the introduction of 
DS-GPA (diagnosis-specific GPA), where 2 points were at-
tributed for KPS 90–100 and a single MBM, 1 point for KPS 
70–80 and 2–3 MBM; the patients with the best prognoses 
had DS-GPA 4 [14, 36–38].
The objective of the study was the retrospective evalua-
tion of the usefulness and the limitations of the application, 
in a clinic, of 3 prognostic scales for patients with MBM. 
Materials and methods 
The analysis concerned 110 subjects (66 men and 44 
women) with MBM, who were treated for melanoma in 
the Oncology Centre in Kraków from 1985–2012. These 
cases accounted for 15.5% all the (710) patients treated for 
melanoma during that period. The diagnosis of MBM was 
made on the basis of imaging diagnostics: computer tomog-
raphy (CT) and/or magnetic resonance imaging (MRI). The 
source of information concerning the pathomorphological 
characteristics of the tumour, clinical data, the course of the 
disease, survival and causes of death was medical documen-
tation (patient information charts, hospital files, the files of 
GPs as well as the state cancer registers (in cases when it was 
necessary). Table I presents the clinical characteristics of the 
pathomorphological characteristics of the patients’ tumours.
The mean age of the subjects was 55 years (range: from 
34 to 72). The average time for the confirmation of the 
Table I. Populational and clinical characteristics of the analysed group 
of 110 melanoma patients with brain metastases
Property Number  
of patients
%
Age (years):
< 50 18 16.4
50–60 68 61.8
61–65 14 12.7
> 65 10 9.1
Sex:
Males 66 60.0
Females 44 40.0
Period free from metastases (months):
< 24 54 49.1
≥ 24 56 50.9
Neurological symptoms:
Present 98 89.1
Absent 12 10.9
Number of brain metastases :
1 40 36.4
2–3 22 20.0
> 3 48 43.6
Control of the primary focus :
Yes 65 59.1
No 45 40.9
Extracranial metastases:
Present 90 81.8
Absent 20 18.2
KPS:
90–100 12 10.9
70–80 60 54.6
< 70 38 34.5
LDH* in blood serum:
≤ 240 UI/mL 46 41.8
> 240 UI/ mL 64 58.2
Total 110 100.0
*LDH — lactate dehydrogenase
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development of the brain metastases, calculated from the 
diagnosis of the melanoma was 31 months (range: from 
0.2 to 145 months). In 89 patients (89.1%), neurological 
symptoms were present (headaches, nausea, epilepsy and 
focal defects), whist in the remaining 12 patients (10.9%) 
clinically asymptomatic brain metastases were found. The 
number of metastatic foci in the brain was the following: 1 in 
40 (36. 4%) subjects, 2–3 in 2 (20%) subjects and more than 
3 in 48 (43.6%) subjects. In 65 (59.1%) the primary disease 
was controlled; in 20 (18.2%) subjects MBM were the only 
location of the metastases, whilst in 90 (81.8%) subjects, 
the brain metastases co-existed with metastases in other 
locations: lungs (72–65.5%), liver (43–39.1%), skin or sub-
cutaneous tissue (35–31.8%), bones (16–14.5%) and other 
locations (spleen, adrenal glands, peritoneum, extraperito-
neal space) — 42 (38.2%). The general performance score 
KPS ≥ 70 was diagnosed in 72 (65.5%) subjects, whereas 
< 70 in 38 (34.5%) subjects. The cut-off values of the lactate 
dehydrogenase (LDH) activity in blood serum were adopted 
to be 240 UI/mL and in 64 (58.2%) subjects an elevated level 
of this enzyme was found [16].
Treatment 
All patients were treated with external beam radiothera-
py (60Co source or 6 MV photon beams). The irradiated area 
comprised the whole brain (WBRT), where the administered 
doses was 40Gy in 20 fractions with the use of the opposite 
fields technique. Out of 110 subjects, in 76 (69.1%) of them, 
solely WBRT was applied and in 14 (12.7%) subjects WBRT 
was combined with temozolomide (200 mg/m2, 5 days in 
cycles every 28 days), whilst in 12 (10.9%) cases, WBRT was 
used as an adjuvant treatment after a neurosurgical inter-
vention; in 8 (7.3%) subjects WBRT was applied after radio-
surgery (SRS). It must be pointed out that the patients with 
isolated metastatic foci were treated with neurosurgery and, 
if the tumour was non-resectable — they were treated by 
radiosurgery with the dose of 15–25 Gy in 1 fraction.
Statistical analysis 
The evaluation criterion was adopted to be the survival 
period calculated from the MBM diagnosis till the death 
date, or, in the case of survival patients, till the last follow-
-up visit. The survival curves and the average survival with 
95% relative confidence intervals (95% CI) were evaluated 
with the Kaplan Meier method and then compared with the 
log-rank test. There were single and multivariance analyses 
carried out with the Cox method. In all the statistical analy-
ses, the significance level was adopted for p ≤ 0.05.
Results
Survivals and prognostic factors 
In the analysed group, the mean survival period cal-
culated from the MBM diagnosis was 4.8 months (95% CI; 
4.1–5.2 months). Depending on the applied methods of the 
MBM treatment, this value was: 9.2 months (surgery and 
WBRT); 7.4 months (SRT and WBRT); 4 months (solely WBRT) 
and 3.8 months (WBRT + temozolomide).  In all subjects, the 
6- and 12 month survival periods were 39.1% and 13.6% 
respectively. Figure 1 presents the survival curve for a group 
of 110 subjects with MBM.
The results of one-way analysis of variance showed that 
favourable prognostic factors were: KPS ≥ 70, the presence 
of a single MBM focus and the lack of metastases in other 
(extracranial) locations (Tab. II). However, in relation to sex, 
age, the period of development of brain metastases, the 
presence of neurological symptoms, the control of the pri-
mary disease and the LDH blood serum level, no prognostics 
value was found. 
Table III presents the final model of the Cox multivariate 
analysis. It was found that independent prognostic factors 
for patients with MBM were the general performance (KPS) 
Figure 1. Survival curve of 110 melanoma patients with brain 
metastases
Table II. Statistically significant prognostic factors in reference to survival
Factor Mean survival period 
(months)  
(95% confidence interval)
p
KPS:
90–100 7.6 (6.1–17.0) < 0.001
70–80 5.4 (4.2–6.7)
< 70 3.8 (0.4–4.1)
The number of MBM foci:
1 7.6 (5.8–17.0) < 0.001
2–3 4.9 (3.7–5.9)
> 3 3.4 (0.4–3.9)
Extracranial metastases:
Present 6.2 (4.7–17.0) 0.0465
Absent 4.2 (0.4–5.2)
KPS — Karnofsky Performance Status; MBM — melanoma brain metastases
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and the number of the MBM. Figures 2 and 3 present the 
probability of survival as a function of these two prognostic 
factors.
Analysis of the usefulness of the clinical 
application of prognostic scales: RPA-RTOG, GPA 
and MS-GPA in patients with MBM
Assigning patients to specific groups of the evaluated 
prognostic scales was as follows: 
 — According to RPA-RTOG — 20 (18.2%) patients met the 
criteria of class I, whilst 90 (81.8%) subjects met the 
criteria of classes II and III;
 — According to GPA — 18 (16.4%) patients met the criteria 
of class I and II, and 92 (83.6%) subjects met the criteria 
of classes III and IV; 
 — According to MS-GPA — 40 (36.4%) patients met the 
criteria of classes I–II, and 70 (63.6%) subjects met the 
criteria of classes III–IV. 
Table IV lists the survival results of the patients with MBM 
depending on the prognostic scale index.
It was found that in the classes which were characterised 
with the best prognoses (i.e. RPA-RTOG — I group, GPA — 
I and II group and MS-GPA — I and II group) the mean values 
of the survival period were comparable and amounted to 
between 7.2 and 10.7 months. In the classes with the worst 
prognoses (i.e. RPA-RTOG group II and III, GPA — III and IV as 
well as MS-GPA — III and IV), the mean survival periods were 
also comparable, yet shorter (from 2.6 to 4.3 months) than 
in patients assigned to the groups with better prognoses.
Table III. The results of Cox multivariance analysis
Variant Relative 
risk
95% 
confidence 
interval
p
KPS:
90–100 1.00 < 0.001
70–80 1.47 0.7–2.6
< 70 3.15 1.7–6.1
MBM number:
1 1.00 0.003
2–3 1.52 0.92–2.43
> 3 1.98 1.41–3.3
Extracranial metastases:
Present 1.00 0.176
Absent 1.18 0.7–1.56
KPS — Karnofsky performance status; MBM — melanoma brain metastases
Figure 3. Survival curve of 110 melanoma patients with brain 
metastases, related to the number of metastatic foci
Figure 2. Survival curve of 110 melanoma patients with brain 
metastases, related to their general status
Table IV. Mean survival period depending on the patient’s assigning 
to specific classes of the evaluated prognostic indices (RPA-RTOG, GPA 
and SM-GPA)
Prognostic 
indices
Number of 
subjects (%)
Average survival 
period (months)
(95% confidence 
interval)
p
The entire 
group
110 (100.0) 4.8 (0.4–17.0)
RPA-RTOG :
I 20 (18.2) 9.6 (6.0–17.0) < 0.002
II 52 (47.3) 4.5 (1.9–8.4)
III 38 (34.5) 2.6 (0.4–3.8)
GPA:
I 8 (7.3) 10,7 (5.8–17.0) < 0.002
II 10 (9.1) 7.2 (6.0–8.1)
III 22 (20.0) 3.8 (1.8–5.7)
IV 70 (63.6) 2.7 (0.4–3.9)
MS-GPA:
I 12 (10.9) 10.4 (6.8–17.0) < 0.001
II 28 (25.5) 8.2 (6.0–1.0)
III 22 (20.0) 4.3 (1.0–5.4)
IV 48 (43.6) 3.1 (0.4–4.1)
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Discussion
The objective of this analysis was to evaluate the useful-
ness of the application, in a clinic, of 3 prognostic scales (RPA- 
-RTOG, GPA and MS-GPA) in reference to patients with MBM, in 
whom various therapeutic methods were used. The methods 
of treatment used in the analysed group of patients were 
similar to those discussed in the publications and concerned 
retrospective studies [3, 5–8, 13, 16, 37, 39–45]. Table V pre-
sents the site’s results and those presented by other authors.
The results of the multivariance analysis pointed out that 
the KPS and MBM number were independent prognostic 
factors in the patients with MBM. The published data defini-
tively indicate the prognostic value of KPS; in the majority of 
publications, the statistically significant adverse prognostic 
factor is a KPS below 70 [5–8, 14, 16, 17, 30, 32–36], whilst in 
other publications, this concerns a KPS below 80 [7, 32, 33]. 
Table VI presents the values of average survival periods 
of patients with MBM depending on the KPS score, which 
were 5.9–6.3 months for KPS ≥ 70 and were definitely lower 
in patients with a poorer general performance (KPS < 70), 
where they varied from 1.8 to 3.8 months. The results based 
on the site’s material are comparable with those presented 
with other authors [5, 13, 14, 37, 40, 46].
Table V. Treatment results in patients with melanoma metastases in brain in published data
Author [number in bibliography list], year of publication Mean survival period (months) Remarks
Konstadoulakis et al. [28], 2000 3.9 12-month survival:
surgery + SRS and/or WBRT — 28.3%
radiotherapy — 6.7%
not treated subjects — 3.5%
Buchsbaum et al. [13], 2002 5.5 –
Harrison et al. [6], 2003 4.0 –
Fife et al. [42], 2004 4.1 –
Meier et al. [43], 2004 4.8 Survival:
6 months — 36%
12 months — 14%
24 months — 5%
Raizer et al. [44], 2008 5.2 –
Staudt et al. [40], 2010 5.0 –
Eigentler et al. [5], 2011 5.0 –
Davies et al. [1], 2011 4.7 –
Zakrzewski et al. [41], 2011 5.8 –
Partl et al. [16], 2013 2.3 Only WBRT 
Zakauskaite et al. [45], 2013 4.5 MBM without neurological symptoms
12-month survival — 12.5%
Presented study, 2016 4.8 Survival:
6 months — 35.1%
12 months — 13.6%
MBM — melanoma brain metastases; SRS — stereostatic radiosurgery; WBRT — whole brain radiotherapy
Table VI. Mean survival in correlation with Karnofsky performance 
status (KPS)
Author [number in bibliography list], 
year of publication
KPS Mean OS 
(months)
Buchsbaum et al. [13], 2002 ≥ 70 6.3
< 70 1.8
Gaudy-Marqueste et al. [7], 2006 > 80 5.98
≤ 80 2.25
Mathieu et al. [46], 2007 90–100 6.3
< 90 2.9
Staudt et al. [40], 2010 > 80 6.0
≤ 80 3.0
Eigentler et al. [5], 2011 ≥ 70 6.0
< 70 3.0
Nieder et al. [37], 2011 90–100 15.1
70–80 4.6
< 70 2.0
Marcus et al. [14], 2014 90–100 10.4
70–80 6.1
< 70 4.5
Presented study 2016 ≥ 70 6.2
< 70 3.9
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The other, generally accepted prognostic factor is the 
number of MBM foci. The best prognoses concerned the 
patients with a single metastatic focus [17, 32, 35, 36, 40]; the 
increase of the MBM number is associated with a deteriora-
tion of the patient’s prognosis [17, 32, 35, 36]. 
Staudt et al. claim that relatively good prognoses can 
only be made in patients with a single metastatic focus [40]. 
Rades et al. in turn, distinguishes two groups of patients: 
with 1–3 MBM foci and with more than 3 MBM foci; and 
Weltman and Sperduto propose breaking down the patient 
groups into 3 categories: with 1, with 2–3 and more than 
3 MBM [32, 34, 36]. 
Table VII presents the mean survival periods of patients 
with MBM depending on the number of metastatic foci in 
the brain, and thus in the case of isolated metastases the 
survival periods were 5.9–8 months and were twice as short 
in the case of multiple MBMs. In this case also the site’s ex-
perience was compared with the results published by other 
authors [1, 5, 13, 14, 37, 40, 46].
Some investigators point to the adverse prognos-
tics significance of the presence of metastases outside 
the brain, in particular in the lungs, liver, spleen and 
adrenal glands, and, to a lesser degree, in the bones, 
lymph nodes and skin [5, 6, 8, 30, 31, 33–35, 40–42]. 
In the site’s own material, in a single-variance analysis, 
it was shown that the co-existence of the metastases 
in extracranial locations was an adverse prognostic factor, 
which was, however, not confirmed by the results of the 
multivariance analysis. According to the published data, 
the factors which play a prognostic role are also the age, 
blood serum LDH level before treatment, the time of MBM 
onset and the presence of neurological symptom as well 
as the control degree of the primary disease [5, 7, 8, 14, 
30, 32–35, 40–42, 45].
Table VII. Mean survival in correlation with the MBM number
Author [number in bibliography 
list], year of publication
MBM 
number
Mean survival  
(months)
Buchsbaum et al. [13], 2002 1 7.9
> 1 4.6
Gaudy-Marqueste et al. [7], 2006 1 5.49
> 1 4.56
Mathieu et al. [46], 2007 1 6.8
> 1 3.6
2–3 4.5
4–6 3.2
> 6 2.4
Staudt et al. [40], 2010 1 8.0
2 5.0
> 2 3.0
Eigentler et al. [5], 2011 1 7.0
> 1 4.0
Davies et al. [1], 2011 1–3 5.92
> 3 3.52
Nieder et al. [37], 2011 1 5.9
2–3 3.7
> 3 3.1
Marcus et al. [14], 2014 1 7.8
2–3 6.0
> 3 3.8
Presented study, 2016 1 7.6
2–3 4.9
> 3 3.4
Table VIII. Mean survival in correlation with the class in RPA-RTOG scale
Author [number in 
bibliography list], year  
of publication 
Prognostic  
class
Mean survival 
(months)
Buchsbaum et al. [13], 2002 I 10.5
II 5.9
III 1.8
Harrison et al. [6], 2003 I 6.5
II 3.5
III 2.5
Morris et al. [8], 2004 I 5.0
II 2.4
III < 1
Staudt et al. [40], 2010 I 9.0
II 5.0
III 2.0
Eigentler et al. [5], 2011 I 7.0
II 5.0
III 3.0
Presented study, 2016 I 9.6
II 4.5
III 2.6
Table VIII, IX and X present the survival periods of pa-
tients with MBM depending on their assignment to specific 
classes within the prognostic scales RPA-RTOG, GPA and 
MS-GPA. 
In the case of the RPA-RTOG scale, it was found that 
the mean survival period of the patients assigned to class I 
was 5–10.5 months, whilst in class II: 2.4–5.9 months and in 
class III < 1–3 months; the presented results, based on the 
site’s data, are similar to those published by other authors.
The above-discussed author’s own observations and the 
published data point both to the benefits and limitations 
related to the use of prognostic indices in patients with 
MBM [13, 35, 37, 42, 47].
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1. The benefits connected with the use of the prognostic 
indices (RPA-RTOG, GPA, MS-GPA):
 — Allow for the patients’ classification with regards to their 
prognoses;
 — Facilitate the choice of the treatment method: from 
more aggressive for patients with a chance of a prolon-
gation of the survival period and alleviation of symp-
toms to less aggressive for patients with the advanced 
disease; all the 3 indices (in particular GPA and MS-GPA) 
allow for the identification of patients with favourable 
prognosis, which might be useful for the qualification 
of patients for surgical treatment or SRS;
 — Assist in the determination of the classification criteria 
for clinical trials;
 — Facilitate the comparison of the homogeneity of the 
patient groups for retrospective analysis.
2. The limitation of the prognostic indices:
 — The discussed indices (RPA-RTOG, GPA, MS-GPA) do not 
fully distinguish between the groups with adverse prog-
nosis (RPA-RTOG class II vs class III, GPA and MS-GPA 
class III (BSC);
 — RPA-RTOG does not take into consideration the number 
of MBM foci; the RTOG 9508 study showed that the 
number of MBM foci is a significant prognostic factor; 
the results of the author’s multivariance analysis showed 
that the KPS and MBM foci number were independent 
prognostic factors. Moreover, the RPA-RTOG index re-
quires control over the metastatic foci located outside 
the brain, which is difficult in evaluation and/or bur-
dened with significant subjectivity;
 — MS-GPA takes into consideration solely the KPS and 
MBM foci number, whereas a few large studies showed 
that the presence of extracranial metastases is a signifi-
cant prognostic factor, which is also confirmed by the 
author’s own research [8, 47].
Conclusions
The introduction of prognostic indices to everyday 
clinical practice as well as their continual improvement are 
indicative of a progress in the treatment of MBM patients. 
Yet, these indices should be used with appropriate caution 
and critical evaluation.
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